Cargando…

A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study

OBJECTIVE: Older cancer patients are underrepresented in the pivotal trials of checkpoint inhibitors (CPIs). This study aimed to investigate the impact of an ageing immune system on CPI-related toxicity and provide evidence for the role of geriatric assessments with CPI. METHODS: The ELDERS study is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomes, F., Lorigan, P., Woolley, S., Foden, P., Burns, K., Yorke, J., Blackhall, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844568/ https://www.ncbi.nlm.nih.gov/pubmed/33516147 http://dx.doi.org/10.1016/j.esmoop.2020.100042

Ejemplares similares

Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
por: Paderi, Agnese, et al.
Publicado: (2021)

Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer
por: Tinsley, N., et al.
Publicado: (2022)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
por: Cantini, Luca, et al.
Publicado: (2023)

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy
por: Higham, C E, et al.
Publicado: (2018)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
por: Mandala, Mario, et al.
Publicado: (2021)

The Role of Electronic Patient-Reported Outcome Measures in Assessing Smoking Status and Cessation for Patients with Lung Cancer
por: Convill, James, et al.
Publicado: (2022)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023)

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
por: Switzer, Benjamin, et al.
Publicado: (2021)

Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly Patients: A Retrospective Study
por: Zhang, Jian, et al.
Publicado: (2023)

Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan
por: Hsu, Jason C., et al.
Publicado: (2018)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
por: Gong, Xiaoling, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
por: Chikaishi, Yasuhiro, et al.
Publicado: (2021)

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
por: Baka, S, et al.
Publicado: (2008)

The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study
por: Elias, Alexandra W., et al.
Publicado: (2017)

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
por: Cluxton, Christopher, et al.
Publicado: (2023)

A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
por: Shi, Yue, et al.
Publicado: (2022)

A prospective cohort study of the safety of breast cancer surgery during COVID-19 pandemic in the West of Scotland
por: Romics, Laszlo, et al.
Publicado: (2020)

Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
por: Daoussis, Dimitrios, et al.
Publicado: (2020)

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022)

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer
por: Morinaga, Daisuke, et al.
Publicado: (2023)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
por: Lee, Karla A., et al.
Publicado: (2022)

Wealth and mortality at older ages: a prospective cohort study
por: Demakakos, Panayotes, et al.
Publicado: (2016)

A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need
por: Harle, Amélie, et al.
Publicado: (2020)

Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
por: Raufi, Ali, et al.
Publicado: (2017)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021)

Safety of bronchodilator reversibility test in elderly subjects: a prospective study
por: Dor-Wojnarowska, Anna, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Delirium in elderly postoperative patients: A prospective cohort study
por: Muzzana, Chiara, et al.
Publicado: (2022)

Mortality in Elderly Patients Taking Furosemide: Prospective Cohorts Study
por: Rodríguez-Molinero, Alejandro, et al.
Publicado: (2022)

Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study
por: Nishikawa, Tatsuya, et al.
Publicado: (2022)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
por: Makaremi, Shima, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou, Wenlu, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
por: Zhang, Dongming, et al.
Publicado: (2022)

Are dietary patterns in early childhood associated with alcohol consumption at the age of 17 years? Analysis of data from the Avon Longitudinal Study of Parents and Children (ALSPAC) prospective cohort study
por: Yorke, Katherine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7hth0lj784miqesff2tes55r6f